Last updated: March 2026
Raloxifene (Evista) is a second-generation SERM originally developed for osteoporosis in postmenopausal women. Clinical research shows it's the most effective SERM for gynecomastia — outperforming tamoxifen with 86% response rate versus 41%. It blocks estrogen strongly at breast tissue while preserving bone.
Raloxifene is a selective estrogen receptor modulator with strong antagonist activity in breast tissue and partial agonist activity in bone. Unlike tamoxifen, it has no agonist activity in the uterus.
Raloxifene binds estrogen receptors in breast tissue with high affinity and blocks estrogen-driven proliferation. Its breast antagonism is considered stronger than tamoxifen's, which may explain the superior gynecomastia response rates.
In bone tissue, raloxifene acts as an estrogen agonist, maintaining bone mineral density. FDA-approved for osteoporosis prevention in postmenopausal women. In men, this provides similar bone protection during hormonal transitions.
Raloxifene does block pituitary estrogen receptors and increases LH/FSH, but less potently than tamoxifen or clomiphene. Not ideal as a standalone PCT agent — better combined with tamoxifen for testosterone recovery.
Unlike tamoxifen, raloxifene has no agonist activity in the uterus. In women, this means no increased endometrial cancer risk. In men, this is less relevant but indicates a cleaner receptor profile overall.
Data from gynecomastia trials, osteoporosis studies, and comparative SERM research.
Raloxifene dosing for gynecomastia, PCT support, and bone health.
| Protocol | Dose | Duration | Notes |
|---|---|---|---|
| Gynecomastia Treatment | 60mg/day | 3-9 months | Most effective for existing gyno. Take with food. Response usually seen by month 2-3. |
| Gyno Maintenance | 30mg/day | Ongoing | After initial response, some reduce to maintenance dose. |
| PCT Combo (with Tamoxifen) | 60mg/day | 4-6 weeks | Add to tamoxifen PCT if gyno is a concern. Tamoxifen handles LH; raloxifene handles breast. |
| On-Cycle Gyno Prevention | 60mg/day | As needed | If gyno symptoms appear on cycle, raloxifene can be added to AI protocol. |
| Osteoporosis (women) | 60mg/day | Long-term | FDA-approved indication. Reduces vertebral fractures 35%. |
How raloxifene compares to other SERMs for gynecomastia and PCT.
Best for gynecomastia. Weaker LH stim. 60mg/day.
Better for PCT/LH recovery. 20-40mg/day. Still works for gyno.
Strongest LH boost. Poor choice for gyno. Visual side effects.
Between tamoxifen and raloxifene. Less data. 60mg/day.
Important interactions to consider when using raloxifene.
Reduces raloxifene absorption by 60%. Separate dosing by at least 2 hours if both are necessary.
Raloxifene can decrease warfarin effect (opposite of tamoxifen). Monitor INR and adjust anticoagulant dose as needed.
Do not combine with estrogen therapy. Raloxifene blocks estrogen receptors — defeats the purpose of HRT.
Can be stacked for PCT — tamoxifen for LH/testosterone, raloxifene for gyno. Monitor for additive side effects (hot flashes, DVT risk).
Primary research supporting raloxifene's use for gynecomastia.
Raloxifene 60mg/day achieved 86% response rate vs 41% for tamoxifen 20mg/day in adolescent males with pubertal gynecomastia. Raloxifene group had greater breast volume reduction.
PMID: 15238910 →Raloxifene 60mg/day reduced vertebral fractures by 30-50% and maintained bone mineral density in postmenopausal women. No increased endometrial cancer risk vs placebo.
PMID: 10458216 →Raloxifene was as effective as tamoxifen for reducing invasive breast cancer risk in high-risk postmenopausal women, with fewer thromboembolic events and cataracts.
PMID: 16769748 →Support supplements and monitoring supplies.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Raloxifene is a prescription medication. Off-label use for gynecomastia in men is not FDA-approved. Always consult a qualified physician before starting any hormone therapy.